A survey published this week by Hone Health has put some hard numbers behind something many in the peptide research community have suspected for a while: a significant portion of people using peptides don’t fully understand what they’re taking or how it’s regulated.
The Numbers
The May 2026 survey of 2,491 US adults who had at least some familiarity with peptides found that 50% of current peptide users mistakenly believe the compounds they’re using are FDA-approved. They’re not - at least not the ones most people in the research community are interested in.
The survey also found that 60% of peptide users are taking at least one compound classified as research-grade. These are peptides that cannot legally be compounded into prescription medications and are typically produced overseas without FDA oversight.
Why This Matters
The distinction between FDA-approved peptides and research-grade compounds isn’t just regulatory paperwork. It affects everything from manufacturing standards to safety data availability.
FDA-approved peptides - like insulin or semaglutide - are manufactured under current Good Manufacturing Practice (cGMP) standards. Every batch is tested for potency and purity, carries a lot number for traceability, and is dispensed through licensed pharmacies with a prescription.
Research-grade peptides operate in a completely different world. They’re typically produced in bulk overseas with no FDA oversight, which means there’s no guarantee of what’s actually in the vial. A January 2026 analysis found that roughly 3 in 10 research-grade peptide products fail basic quality checks - they’re mislabeled, below purity thresholds, or dosed incorrectly.
There’s also no lot tracking, no requirement to report adverse events, and no one systematically collecting safety data. If someone has a reaction to a research-grade peptide, there’s no formal mechanism for that information to be captured and shared.
The Three Categories
Understanding the regulatory landscape helps explain why the survey results aren’t surprising. Peptides essentially fall into three categories:
FDA-approved drugs - These include insulin, GLP-1 medications like semaglutide and tirzepatide, and other compounds that have completed clinical trials and are manufactured under strict regulatory oversight. These are dispensed through pharmacies with prescriptions.
Category 1 (503A Bulks List) - Compounds like sermorelin that can be prescribed through compounding pharmacies under physician supervision. They have purity and labelling oversight but haven’t gone through the full FDA approval process.
Research-grade - The largest and most popular category in the peptide community. These compounds cannot legally be compounded into prescription medications. BPC-157, TB-500, MOTs-C, and many other peptides that generate significant community interest fall into this category.
The gap between what people think they’re taking and what they’re actually taking is most pronounced in that third category. When someone orders BPC-157 online, they may assume it’s regulated similarly to a prescription medication. It isn’t.
What the Research Says
The quality issue isn’t theoretical. Multiple analyses have documented significant variability in research-grade peptide products. Some contain less than the labelled amount of active compound. Others contain contaminants from the manufacturing process. A few have been found to contain entirely different compounds than what was on the label.
Dr Abid Husain, a triple-board-certified physician specializing in peptide therapy, put it plainly in the Hone Health report: “Peptides can help you reach your health goals if they’re medical-grade and taken under professional supervision. If not, you’re playing roulette with your health.”
The effects of peptides can also vary significantly between individuals. Growth hormone-releasing peptides, for example, increase IGF-1 levels. For someone with naturally low IGF-1, that might be beneficial. For someone whose levels are already elevated - from a pituitary issue or natural biological variation - the same peptide could increase risk for certain conditions.
The Bigger Picture
The survey comes at a significant moment. The FDA is holding an advisory committee meeting in late July to review whether several popular research-grade peptides should be added to the 503A Bulks List. If approved, that would create a legal pathway for compounding pharmacies to manufacture them - which would automatically improve quality assurance.
But the survey data suggests that even if the regulatory pathway opens, there’s a knowledge gap that needs closing. People are making decisions about peptide use without a clear understanding of the evidence base, the regulatory status, or the quality risks involved.
For the Australian research community, the findings are a useful reminder to verify sourcing and understand what you’re actually getting. The TGA’s approach to peptide regulation differs from the FDA’s, but the quality concerns around unregulated research compounds are universal.
Sources
Source: 50% of peptide users are taking compounds not approved for human use. Most don’t know it (Hone Health via AOL, 30 June 2026)
Source: Peptides Aren’t Actually Legal Yet, Here’s What Has to Happen Before RFK Jr.’s 2026 Plan Takes Effect (The News & Observer, 17 June 2026)
Source: Peptide interest is growing fast, but the FDA’s actual 2026 docket is far smaller than reported (Charlotte Observer, 17 June 2026)
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.